IP Library Granted Patent US 7,483,755
Granted Patent B2
US 7,483,755 · App. 10/463,976 · Granted Jan 27, 2009

Devices, methods, and systems for shrinking tissues

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,483,755
App. No.
10/463,976
Granted
Jan 27, 2009
Kind
B2
Abstract

Devices, systems, and method for treating urinary incontinence generally rely on energy delivered to a patient's own pelvic support tissue to selectively contract or shrink at least a portion of that pelvic support tissue so as to reposition the bladder. The energy will preferably be applied to the endopelvic fascia and/or an arcus tendineus fascia pelvis. The invention provides a variety of devices and methods for applying gentle resistive heating of these and other tissues to cause them to contract without imposing significant injury on the surrounding tissue structures. Alternatively, heat-applying probes are configured to heat tissue structures which comprise or support a patient's urethra. By applying sufficient energy over a predetermined time, the tissue can be raised to a temperature which results in contraction without significant necrosis or other tissue damage. By selectively contracting the support tissues, the bladder neck, sphincter, and other components of the urinary tract responsible for the control of urinary flow can be reconfigured or supported in a manner which reduces urinary leakage.

Claims (47)

1. A method to treat urinary stress incontinence, the method comprising:

introducing a probe into a patient body;

aligning the probe with a collagenous pelvic tissue which supports the urethra within the patient body; and

energizing the probe to heat a portion of the pelvic support tissue so that the pelvic support tissue is contracted to inhibit incontinence.

2. A method as claimed in claim 1 , further comprising engaging first and second electrodes against the pelvic support tissue and applying an electrical potential across the first and second electrodes to heat a portion of the pelvic support tissue disposed therebetween so as to reposition a bladder neck within the patient body.

3. A method as claimed in claim 2 , further comprising monitoring a temperature of the heated tissue with a temperature sensor of the probe, the sensor being in thermal contact with the heated tissue.

4. A method as claimed in claim 2 , wherein the first and second electrodes engage the pelvic support tissue with a predetermined electrode surface diameter and spacing between the electrodes to limit a tissue heating depth.

5. A method as claimed in claim 4 , wherein the depth of tissue heating is less than about 2.0 mm, a surface diameter of the electrodes being between about 0.25 and 4.0 mm, the spacing between the first and second electrodes being between about 1 and 4 times the electrode surface diameter.

6. A method as claimed in claim 2 , further comprising sweeping the first and second electrodes across the pelvic support tissue while applying the electrical potential to heat a band of the pelvic support tissue substantially bordered by swept paths of the first and second electrodes.

7. A method as claimed in claim 1 , wherein the electrical potential has a frequency of between about 100 and 1,000 khz and an amplitude of between about 20 and 200 volts rms.

8. A method as claimed in claim 7 , wherein the pelvic support tissue reaches a maximum temperature of between about 60° C. and 110° C. for a time between about 0.5 and 5.0 seconds.

9. A method as claimed in claim 1 , further comprising monitoring a temperature of the pelvic support tissue while heating.

10. A method as claimed in claim 1 , wherein the aligning step comprises laparoscopically imaging the pelvic support tissue.

11. A method as claimed in claim 1 , wherein the introducing step comprises inserting the probe while the probe is in a narrow configuration, and further comprising deploying at least one of the first and second electrodes to a wide configuration prior to the heating step, the wide configuration being wider than the narrow configuration.

12. A method as claimed in claim 1 , further comprising laterally repositioning a bladder neck within the patient body by heating an alternative portion of the pelvic support tissue.

13. An endoscopic method for treating urinary stress incontinence, the method comprising:

introducing a probe into a patient body;

optically imaging the probe and a target tissue of the patient body, the target tissue comprising a portion of at least one of an endopelvic fascia and an arcus tendineus fascia pelvis which support the patient's urethra;

positioning an electrode of the probe against the target tissue; and

energizing the electrode to heat and contract the target tissue without substantially ablating the target tissue.

14. An endoscopic method as claimed in claim 13 , further comprising engaging first and second electrodes against the target tissue and applying an electrical potential across the first and second electrodes to heat a portion of the target tissue disposed therebetween, wherein the first and second electrodes engage the fascia with a predetermined spacing therebetween to limit a depth tissue heating and to avoid damaging tissue below the target tissue.

15. A method for treating urinary incontinence in a patient, said method comprising applying an amount of energy to a collagenous tissue structure supporting the patient's urethra wherein the amount of energy is sufficient to cause partial shrinkage of the tissue and the tissue shrinkage inhibits urinary incontinence.

16. A method as in claim 15 , wherein the tissue structure is selected from the group consisting of a region of the urethra suspension ligaments, pelvic ligaments, pelvic floor muscles, and fascia.

17. A method as in claim 16 , wherein the tissue structure comprises the pubococcygeal muscle, the iliococcygeal muscle, or the detrusor muscle and adjacent fascia, and the applying step comprises penetrating an energy-applying element into the tissue structure from the vagina.

18. A method as in claim 15 , where the amount of energy applied is sufficient to raise the tissue structure to a temperature in the range from 60° C. to 95° C. for a time in the range from 0.5 minute to 4 minutes.

19. A method for treating urinary incontinence in a patient, said method comprising:

inserting a probe into the patient;

advancing a plurality of electrodes from the probe so that the electrodes penetrate a collagenous tissue structure comprising a bladder neck; and

applying electrical energy to the collagenous tissue structure with the electrodes to heat the collagenous tissue structure sufficiently to effect shrinkage of the collagenous tissue structure so that the collagenous tissue structure inhibits urinary incontinence.

20. A method as in claim 19 , wherein the energy is applied as a bipolar RF energy transmitted between the electrodes.

21. A method as in claim 19 , wherein an axis of the probe extends from the proximal end to the distal end with the electrodes extending asymmetrically relative to the axis, wherein two electrodes deploy from the probe to penetrate the collagenous tissue structure on a first lateral side of the probe, and wherein two electrodes deploy from the probe to penetrate the collagenous tissue structure on a second lateral side of the probe.

22. A method as in claim 19 , wherein the collagenous tissue structure further comprises at least one member selected from the group consisting of a urethral wall, a bladder, a ureter, bladder suspension ligaments, a sphincter, pelvic ligaments, pelvic floor muscles, and fascia.

23. A method as in claim 19 , further comprising adjusting a power level of the energy, wherein the adjusting step is performed in response to internal temperature in the collagenous tissue structure.

24. A method for treating incontinence in a patient, said method comprising:

inserting a probe into a urethra of the patient;

electrically coupling at least one electrode of the inserted probe to a collagenous tissue structure;

applying electrical energy to the collagenous tissue structure with the at least one electrode to heat the collagenous tissue structure, wherein the shrinkage provides a kink or closure point along the urethra to inhibit leakage; and

controlling an amount of the energy applied in response to a temperature of the collagenous tissue structure so that the collagenous tissue structure inhibits incontinence.

25. A method as in claim 24 , wherein the energy is applied so as to cause bulking and buttressing of the collagenous tissue structure during healing.

26. A method as in claim 24 , wherein the energy is applied so as to effect shrinkage of the collagenous tissue structure, the shrinkage and tissue bulking/buttressing acting to enhance patient continence.

27. A method for treating urinary incontinence in a patient, said method comprising:

inserting a probe into the patient;

engaging a plurality of electrodes of the probe against a bladder neck; and

applying sufficient electrical energy to the bladder neck so as to inhibit the urinary incontinence.

28. The method of claim 27 , further comprising advancing the electrodes from the probe so that the electrodes penetrate into the bladder neck.

29. The method of claim 27 , further comprising inserting the probe through the urethra.

30. The method of claim 29 , further comprising controlling an amount of the energy in response to a temperature of the bladder neck.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0318. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Sep 6, 2016
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 039919/0017 →
CHANGE OF NAME Recorded Jan 11, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037473/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037473/0260 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0318 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →
RELEASE OF SECURITY INTEREST Recorded Apr 18, 2011
From: CIT HEALTHCARE LLC
To: SOLARANT MEDICAL, INC.
Reel/Frame 026142/0160 →
CORRECTIVE RECORDATION TO CORRECT SERIAL NUMBER 11/463976 ON REEL/FRAME 018087/0904 Recorded Aug 21, 2006
From: SOLARANT MEDICAL, INC.
To: AMS RESEARCH CORPORATION
Reel/Frame 018149/0099 →
SECURITY AGREEMENT Recorded Aug 17, 2006
From: SOLARANT MEDICAL, INC.
To: CIT HEALTHCARE LLC
Reel/Frame 018120/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2006
From: SOLARANT MEDICAL, INC.
To: AMS RESEARCH CORPORATION
Reel/Frame 018087/0904 →
CHANGE OF NAME Recorded Apr 14, 2004
From: SURX, INC.
To: SOLARANT MEDICAL, INC.
Reel/Frame 014523/0207 →